UNSPSC 51291503: Befloxatone

This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18F3NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4H75PAD8M3, chemically known as 2-oxazolidinone, 5-(methoxymethyl)-3-(4-(4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-, (r,(r*,r*))- but generally known as befloxatone, which bears US NIH Compound Identifier 60824. European Medicines Agency schedules Befloxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05681MIG.

UNSPSC 51291503 Befloxatone is a Commodity code with minimal recent state and local procurement activity. The single identifiable solicitation in the record involves naloxone and drug deactivation systems—pharmaceutical and harm-reduction products—rather than befloxatone specifically, suggesting a mismatch between the code assignment and actual procurement needs. Befloxatone is an antidepressant medication; state and local governments do not typically procure individual pharmaceutical compounds directly through competitive bidding. The code shows little relevant recent activity for business development purposes.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The bid was released July 10, 2023, with a response deadline of July 26, 2023, at 2:00 p.m. The contract carries a two-year initial term with one-year renewal option, fixed-fee pricing, and potential FEMA funding. No other state or local opportunities under this code appear in recent activity; the geographic and issuing-body picture cannot be characterized from a single Seminole County procurement.